1111 GMT - U.S. President Trump's plans for 25% tariffs on pharmaceutical imports could threaten the European sector, which relies heavily on the U.S. Swiss pharma giant Roche said it is closely monitoring U.S. legislative developments and assessing any potential impact these could have on its business. The company invested over 11 billion Swiss francs ($12.18 billion) in the U.S. over the last ten years and remains committed to invest there, the company added. GSK's chief executive officer Emma Walmsley said in a media call alongside results that the company will keep a close eye on how the fast-moving tariff situation will play out in the coming weeks. The British pharma company employs around 15000 people in the U.S. and has various R&D centres and manufacturing sites across the country. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 19, 2025 06:12 ET (11:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.